These studies therefore showed that decreased TRPM2 function led to enhanced cytotoxicity after chemotherapy in a TN breast cancer cell line and an ER+ breast cancer cell line, but not in a non-cancerous breast cell line. This evidence concerns the gene ESR1 and breast carcinoma.